Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced the initiation of Study 008A, the first potentially pivotal study with evenamide in patients with schizophrenia.
September 6, 2021
· 7 min read